Prediction of Venous Thromboembolism in Patients With Cancer by Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study
Prediction of Venous Thromboembolism in Patients With Cancer by Measuring Thrombin Generation:...
Ay, Cihan; Dunkler, Daniela; Simanek, Ralph; Thaler, Johannes; Koder, Silvia; Marosi, Christine; Zielinski, Christoph; Pabinger, Ingrid
2011-05-20 00:00:00
Purpose: Patients with cancer are at increased risk of venous thromboembolism (VTE). Laboratory tests measuring the overall thrombophilic tendency might be useful to assess VTE risk. The aim of this study was to investigate thrombin generation, a key process in hemostasis, as predictor of cancer-associated VTE. Patients and Methods: The Vienna Cancer and Thrombosis Study (CATS) is a prospective observational cohort study of patients with newly diagnosed cancer or progression of disease after remission. The study end point is occurrence of objectively confirmed symptomatic or fatal VTE within a follow-up period of 2 years. Thrombin generation was measured with a commercially available assay. Results: One thousand thirty-three patients with malignancies of the breast (n = 151), lung (n = 148), upper (n = 44) and lower gastrointestinal tract (n = 125), pancreas (n = 67), kidney (n = 34), prostate (n = 122), and brain (n = 134) or lymphoma (n = 126), multiple myeloma (n = 26), and other tumor types (n = 56) were observed for a median observation period of 517 days. VTE occurred in 77 patients (7.5%). Patients with elevated peak thrombin (defined as values >= 611 nM thrombin, representing the 75th percentile of the total study population) had an increased risk of VTE with a hazard ratio of 2.1 (95% CI, 1.3 to 3.3, P = .002) in multivariable analysis including age, sex, surgery, chemotherapy, and radiotherapy. The cumulative probability of developing VTE after 6 months was significantly higher in patients with elevated peak thrombin than in those with lower peak thrombin (11% v 4%; log-rank test: P = .002). Conclusion: Measurement of thrombin generation may help identify patients with cancer at high risk of VTE.
http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.pngJournal of Clinical OncologyWolters Kluwer Healthhttp://www.deepdyve.com/lp/wolters-kluwer-health/prediction-of-venous-thromboembolism-in-patients-with-cancer-by-ASjoGZiiIZ
Prediction of Venous Thromboembolism in Patients With Cancer by Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study
Purpose: Patients with cancer are at increased risk of venous thromboembolism (VTE). Laboratory tests measuring the overall thrombophilic tendency might be useful to assess VTE risk. The aim of this study was to investigate thrombin generation, a key process in hemostasis, as predictor of cancer-associated VTE. Patients and Methods: The Vienna Cancer and Thrombosis Study (CATS) is a prospective observational cohort study of patients with newly diagnosed cancer or progression of disease after remission. The study end point is occurrence of objectively confirmed symptomatic or fatal VTE within a follow-up period of 2 years. Thrombin generation was measured with a commercially available assay. Results: One thousand thirty-three patients with malignancies of the breast (n = 151), lung (n = 148), upper (n = 44) and lower gastrointestinal tract (n = 125), pancreas (n = 67), kidney (n = 34), prostate (n = 122), and brain (n = 134) or lymphoma (n = 126), multiple myeloma (n = 26), and other tumor types (n = 56) were observed for a median observation period of 517 days. VTE occurred in 77 patients (7.5%). Patients with elevated peak thrombin (defined as values >= 611 nM thrombin, representing the 75th percentile of the total study population) had an increased risk of VTE with a hazard ratio of 2.1 (95% CI, 1.3 to 3.3, P = .002) in multivariable analysis including age, sex, surgery, chemotherapy, and radiotherapy. The cumulative probability of developing VTE after 6 months was significantly higher in patients with elevated peak thrombin than in those with lower peak thrombin (11% v 4%; log-rank test: P = .002). Conclusion: Measurement of thrombin generation may help identify patients with cancer at high risk of VTE.
Journal
Journal of Clinical Oncology
– Wolters Kluwer Health
Published: May 20, 2011
Recommended Articles
Loading...
References
Tissue factor, thrombin, and cancer
FR Rickles; S Patierno; PM Fernandez
Procoagulant mechanisms in tumour cells
A Falanga; M Panova-Noeva; L Russo
Venous thromboembolism (VTE) in patients with cancer: Epidemiology and risk factors
T Wun; RH White
Cancer, clots and consensus: New understanding of an old problem
GH Lyman; AA Khorana
Cancer-associated thrombosis
RL Bick
Cancer and the prothrombotic state
GY Lip; BS Chin; AD Blann
The measurement and application of thrombin generation
T Baglin
Biomarkers and venous thromboembolism
I Pabinger; C Ay
Thrombin generation, a function test of the haemostatic-thrombotic system
HC Hemker; R Al Dieri; E De Smedt
Thrombin generation testing in routine clinical practice: Are we there yet
JJ van Veen; A Gatt; M Makris
Peak thrombin generation and subsequent venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE) study
PL Lutsey; AR Folsom; SR Heckbert
Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence
A van Hylckama Vlieg; SC Christiansen; R Luddington
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation
G Hron; M Kollars; BR Binder
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism
A Tripodi; C Legnani; V Chantarangkul
Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer
S Eichinger; G Hron; M Kollars
High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study
M Besser; C Baglin; R Luddington
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS)
C Ay; R Simanek; R Vormittag
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study
C Ay; R Vormittag; D Dunkler
High factor VIII levels independently predict venous thromboembolism in cancer patients: The cancer and thrombosis study
R Vormittag; R Simanek; C Ay
Thrombin generation in morbid obesity: Significant reduction after weight loss
L Ay; HP Kopp; JM Brix
American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
GH Lyman; AA Khorana; A Falanga
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (ed 8)
WH Geerts; D Bergqvist; GF Pineo
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study
G Agnelli; G Gussoni; C Bianchini
A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial
H Riess; U Pelzer; G Deutschinoff
Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): A multicentre, randomised phase IIB trial (the UK FRAGEM study)
A Maraveyas; J Waters; R Roy
Development and validation of a predictive model for chemotherapy-associated thrombosis
AA Khorana; NM Kuderer; E Culakova
Prediction of venous thromboembolism in cancer patients
C Ay; D Dunkler; C Marosi
Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism
N Goldenberg; SR Kahn; S Solymoss
Abnormalities of blood coagulation tests in patients with cancer
RL Edwards; FR Rickles; TE Moritz
Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy
S Sallah; A Husain; V Sigounas
The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
